Breaking News Instant updates and real-time market news.

VRTX

Vertex

$163.07

-11.11 (-6.38%)

08:11
10/25/18
10/25
08:11
10/25/18
08:11

Vertex shares likely bounce when market 'settles down,' says Jefferies

Jefferies analyst Michael Yee says Vertex Pharmaceuticals' Q3 report was "in-line if not actually better than consensus." While recent "competitive noise has caused various minor uncertainties," the stock will likely bounce when the broader market "settles down," Yee tells investors in a post-earnings research note. The analyst keeps a Buy rating on the shares with a $210 price target.

VRTX Vertex
$163.07

-11.11 (-6.38%)

10/11/18
JEFF
10/11/18
NO CHANGE
Target $210
JEFF
Buy
Jefferies sees shares of Vertex 'going back up and recovering'
Shares of Vertex Pharmaceuticals (VRTX) have pulled back from recent highs of $190-$195 down to $175 on "risk-off rotation" amid the broader market selloff, Jefferies analyst Michael Yee tells investors in a research note. However, nothing fundamental has happened and Vertex still has the "cleanest growth story in large biotech," Yee contends. The triple pill has confirmed Phase III pivotal data coming Q4 and upcoming competitor Galapagos NV (GLPG) data "probably will eventually disappoint," claims the analyst. He also views CTX001 coming off clinical hold as a "nice positive" and thinks the company's pipeline is likely to start garnering more focus over the next 6-12 months. Yee sees the stock "eventually going back up and recovering" and keeps a Buy rating on Vertex with a $210 price target.
10/18/18
RBCM
10/18/18
UPGRADE
Target $9
RBCM
Outperform
Proteostasis upgraded to Outperform at RBC Capital on positive CF data
As reported earlier, RBC Capital analyst Brian Abrahams upgraded Proteostasis (PTI) to Outperform from Sector Perform and also raised his price target to $9 from $4 following an "impressive" set of data from its phase 2 cystic fibrosis doublet trial. The analyst notes that while it is too soon to determine if it will pose a "competitive threat to developmental CFTR modulators marketed by Vertex Pharma (VRTX), the trial showed "clean, consistent, dose-dependent lung function improvements".
10/18/18
MSCO
10/18/18
NO CHANGE
MSCO
Overweight
Vertex weakness on competitor data an overreaction, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison attributes weakness in shares of Vertex (VRTX) to the fact that potential competitor Proteostasis (PTI) released initial Phase 1 data showing that its doublet achieved a roughly 6% increase in FEV1 in the highest dose, compared with about 5% for the VX-661 doublet in Phase 1/2. However, he would caution over-interpretation of the results, noting that Proteostasis' data includes only about five patients per arm; the high mean FEV1 increase may be the result of a "super-responder"; and doublet data "isn't meaningful given triplets with 10-15% FEV1 improvement will be the new standard of care." The analyst, who sees Vertex's sizeable lead and robust data limiting any competitive risks, keeps an Overweight rating on Vertex shares, which are down about 4% in morning trading.
10/25/18
BMOC
10/25/18
NO CHANGE
Target $192
BMOC
Outperform
Vertex price target lowered to $192 from $204 at BMO Capital
BMO Capital analyst Do Kim lowered his price target on Vertex (VRTX) to $192, saying its in-line Q3 results may be overshadowed by the AbbVie (ABBV) decision to license rights to Galapagos (GLPG) cystic fibrosis program, since the expectation was for the collaboration to dissolve. The analyst adds that while the Galapagos interim data did not make competitive inroads on Vertex therapies, he is still lowering the the FY19 EPS view for the latter to $4.43 from $5.13 on slow ex-U.S. growth amid reimbursement challenges and higher operating expenses. Longer term, Kim keeps his Outperform rating on Vertex.

TODAY'S FREE FLY STORIES

INCY

Incyte

$81.22

0.72 (0.89%)

13:39
05/24/19
05/24
13:39
05/24/19
13:39
Hot Stocks
FDA approves expanded indication for Incyte's Jakafi »

According to a post to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 31

    May

  • 05

    Jun

  • 10

    Jun

  • 11

    Jun

  • 13

    Jun

  • 17

    Jun

MOMO

Momo

$25.94

-0.72 (-2.70%)

13:35
05/24/19
05/24
13:35
05/24/19
13:35
Options
Momo put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 11

    Jun

ALPN

Alpine Immune Sciences

$5.27

-0.34 (-6.06%)

, ADAP

Adaptimmune

$3.62

-0.03 (-0.82%)

13:34
05/24/19
05/24
13:34
05/24/19
13:34
Recommendations
Alpine Immune Sciences, Adaptimmune, Gilead analyst commentary  »

Alpine Immune Sciences…

ALPN

Alpine Immune Sciences

$5.27

-0.34 (-6.06%)

ADAP

Adaptimmune

$3.62

-0.03 (-0.82%)

GILD

Gilead

$66.88

-0.27 (-0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 13

    Jun

  • 17

    Jun

ALPN

Alpine Immune Sciences

$5.27

-0.34 (-6.06%)

, GILD

Gilead

$66.91

-0.24 (-0.36%)

13:30
05/24/19
05/24
13:30
05/24/19
13:30
Hot Stocks
Alpine Immune Sciences reports notice of termination of license pact with Kite »

In a regulatory filing…

ALPN

Alpine Immune Sciences

$5.27

-0.34 (-6.06%)

GILD

Gilead

$66.91

-0.24 (-0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 13

    Jun

NVS

Novartis

$88.00

3.54 (4.19%)

, BIIB

Biogen

$228.00

-1.05 (-0.46%)

13:30
05/24/19
05/24
13:30
05/24/19
13:30
Hot Stocks
ICER says Zolgensma price falls within upper bound of benchmark range »

The Institute for…

NVS

Novartis

$88.00

3.54 (4.19%)

BIIB

Biogen

$228.00

-1.05 (-0.46%)

IONS

Ionis Pharmaceuticals

$65.44

-1.69 (-2.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 31

    May

  • 05

    Jun

  • 06

    Jun

  • 17

    Jun

  • 18

    Jun

GOLD

Barrick Gold

$11.93

-0.03 (-0.25%)

, ABGLF

Acacia Mining

$0.00

(0.00%)

13:23
05/24/19
05/24
13:23
05/24/19
13:23
Periodicals
Barrick CEO tells Reuters Acacia bid reflects Tanzania risk »

Barrick Gold (GOLD) CEO…

GOLD

Barrick Gold

$11.93

-0.03 (-0.25%)

ABGLF

Acacia Mining

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
05/24/19
05/24
13:17
05/24/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
05/24/19
05/24
13:16
05/24/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTSH

Cognizant

$61.83

0.75 (1.23%)

13:12
05/24/19
05/24
13:12
05/24/19
13:12
Hot Stocks
Cognizant CEO buys 19K shares of company stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

  • 23

    Jun

NFLX

Netflix

$355.84

3.61 (1.02%)

, GOOG

Alphabet

$1,144.00

3.45 (0.30%)

13:08
05/24/19
05/24
13:08
05/24/19
13:08
Hot Stocks
Netflix to release 'Little Black Mirror' episodes on YouTube starting May 26 »

Netflix Latin America…

NFLX

Netflix

$355.84

3.61 (1.02%)

GOOG

Alphabet

$1,144.00

3.45 (0.30%)

GOOGL

Alphabet Class A

$1,148.10

3.22 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

  • 03

    Jun

  • 06

    Jun

  • 19

    Jun

  • 19

    Jun

  • 25

    Jun

  • 27

    Oct

13:07
05/24/19
05/24
13:07
05/24/19
13:07
General news
Baker-Hughes Rig Count N. Amer. data reported »

Week of 5/24 Baker-Hughes…

UAL

United Continental

$81.10

0.19 (0.23%)

, BA

Boeing

$356.58

6.01 (1.71%)

13:07
05/24/19
05/24
13:07
05/24/19
13:07
Periodicals
United extending Boeing 737 Max cancellations through August 3, CNBC reports »

United Airlines (UAL)…

UAL

United Continental

$81.10

0.19 (0.23%)

BA

Boeing

$356.58

6.01 (1.71%)

AAL

American Airlines

$29.41

-0.08 (-0.27%)

LUV

Southwest

$51.33

0.36 (0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

  • 12

    Jun

  • 12

    Jun

  • 25

    Jul

  • 13

    Nov

BBY

Best Buy

$64.89

-0.9 (-1.37%)

, SSNLF

Samsung

$0.00

(0.00%)

13:04
05/24/19
05/24
13:04
05/24/19
13:04
Periodicals
Best Buy cancels preorders for Samsung's foldable phone, CNN reports »

Best Buy (BBY) is…

BBY

Best Buy

$64.89

-0.9 (-1.37%)

SSNLF

Samsung

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 30

    May

  • 11

    Jun

BHGE

Baker Hughes

$22.28

-0.78 (-3.38%)

13:03
05/24/19
05/24
13:03
05/24/19
13:03
Hot Stocks
Baker Hughes reports U.S. rig count down 4 to 983 rigs »

Baker Hughes reports that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

V

Visa

$162.59

1.07 (0.66%)

13:02
05/24/19
05/24
13:02
05/24/19
13:02
Hot Stocks
Visa CFO Vasant Prabhu appointed company vice chairman »

Visa announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

EHC

Encompass Health

$59.22

-0.315 (-0.53%)

13:01
05/24/19
05/24
13:01
05/24/19
13:01
Hot Stocks
Encompass Health names Kim Sullivan chief human resources officer »

Encompass Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

IONS

Ionis Pharmaceuticals

$67.35

0.215 (0.32%)

, BIIB

Biogen

$229.80

0.75 (0.33%)

13:01
05/24/19
05/24
13:01
05/24/19
13:01
Hot Stocks
Ionis, Biogen slip after FDA approves Novartis' Zolgensma for SMA treatment »

Shares of Ionis…

IONS

Ionis Pharmaceuticals

$67.35

0.215 (0.32%)

BIIB

Biogen

$229.80

0.75 (0.33%)

NVS

Novartis

$87.21

2.75 (3.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 31

    May

  • 05

    Jun

  • 06

    Jun

  • 17

    Jun

  • 18

    Jun

XRT

S&P Retail Index SPDR

$41.58

-0.09 (-0.22%)

13:00
05/24/19
05/24
13:00
05/24/19
13:00
Options
Size four-way put spread in SPDR Retail Trust as shares extend losses »

Size four-way put spread…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RGNX

Regenxbio

$43.60

1.11 (2.61%)

, NVS

Novartis

$87.13

2.67 (3.16%)

12:53
05/24/19
05/24
12:53
05/24/19
12:53
Hot Stocks
Regenxbio up 6% after Novartis receives FDA approval for Zolgensma »

Regenxbio (RGNX) will…

RGNX

Regenxbio

$43.60

1.11 (2.61%)

NVS

Novartis

$87.13

2.67 (3.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 31

    May

NVS

Novartis

$87.04

2.58 (3.05%)

12:47
05/24/19
05/24
12:47
05/24/19
12:47
Hot Stocks
Novartis says wholesale acquisition cost of Zolgensma $2.125M »

AveXis, a Novartis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

TIVO

TiVo

$6.87

0.04 (0.59%)

12:45
05/24/19
05/24
12:45
05/24/19
12:45
Options
TiVo call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

12:45
05/24/19
05/24
12:45
05/24/19
12:45
General news
Breaking General news story  »

Week of 5/24 Baker-Hughes…

VWAGY

Volkswagen

$0.00

(0.00%)

12:42
05/24/19
05/24
12:42
05/24/19
12:42
Periodicals
Appeals court rules in favor of Volkswagen diesel car owners, Reuters reports »

A German appeals court…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNC

Centene

$56.30

0.85 (1.53%)

, WCG

WellCare

$267.57

-6.89 (-2.51%)

12:42
05/24/19
05/24
12:42
05/24/19
12:42
Periodicals
Third Point confirms Centene stake to CNBC, says WellCare deal in best interest »

CNBC tweeted: "Third…

CNC

Centene

$56.30

0.85 (1.53%)

WCG

WellCare

$267.57

-6.89 (-2.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 14

    Jun

  • 24

    Jun

  • 24

    Jun

  • 23

    Jul

SPY

SPDR S&P 500 ETF Trust

$282.86

0.67 (0.24%)

, IVV

iShares Core S&P 500

$284.83

0.69 (0.24%)

12:40
05/24/19
05/24
12:40
05/24/19
12:40
Technical Analysis
On The Fly: ETF fund flow highlights »

Flows for the past week…

SPY

SPDR S&P 500 ETF Trust

$282.86

0.67 (0.24%)

IVV

iShares Core S&P 500

$284.83

0.69 (0.24%)

XLK

Technology Select Sector SPDR

$73.62

0.33 (0.45%)

SMH

Market Vectors Semiconductor

$100.37

0.23 (0.23%)

SOXX

iShares PHLX Semiconductor ETF

$180.13

0.06 (0.03%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$119.60

0.14 (0.12%)

EEM

iShares MSCI Emerging Markets ETF

$40.00

0.08 (0.20%)

XLU

Utilities SPDR

$59.99

0.07 (0.12%)

XLV

Health Care Select Sector SPDR

$89.56

0.17 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.